

Biomedical Interventions for HIV Prevention

A Project of the Forum for Collaborative HIV Research
In collaboration with the Bill & Melinda Gates Foundation

Project Report Summary

IOM


February 6, 2007
Washington, DC

Veronica Miller
Director, FCHR

**Forum for Collaborative
HIV Research**

**School of Public Health &
Health Services**

**The George Washington
University**



The Forum for Collaborative HIV Research is a public/private partnership including government agencies, industry, HIV researchers and clinicians, payors, foundations and the HIV patient advocacy community.


Our mission is to facilitate and enhance HIV research.

**Forum for Collaborative
HIV Research**

**School of Public Health &
Health Services**


**The George Washington
University**

The Forum Executive Committee




- Government Agencies
 - US DHHS (NIH, CDC, FDA, HRSA), State Department (OGAC, USAID)
 - European Regulatory: EMEA
- Industries
 - Abbott, Bayer Diagnostic, BD Biosciences, Boehringer Ingelheim, Bristol-Myers Squibb, Eurofins-Viralliance, Gilead Sciences, GlaxoSmithKline, Merck, Monogram BioSciences, Panacos, Roche Laboratories, Roche Molecular Systems, Pfizer, Schering-Plough, Tibotec, VIRxSYS
- Payors: Kaiser Permanente
- Academia
 - US and Europe
- Providers
- Patient Advocacy
 - US and Europe
- Foundations & Organizations (Gates, amFAR, IAS, ANAC)

Question for HIV Prevention Research Community




- What needs to be done to advance prevention research?
 - How can we get there more quickly?
 - What is holding us back?
- Have we covered all the bases?

Forum project – priorities for research




- Research agenda: what are the criteria for setting research priorities?
 - Feasibility & realism
 - probability of success
 - Development & implementation cost vs potential impact on the epidemic
 - beyond “how good is the science”
- Moving from the “silo” approach to an integrated agenda
 - Prevention & Treatment
 - Within Prevention Research Field
 - Identifying the overlapping common ground critical to share to advance productivity


Working Group Meeting September 18-19, 2006



- Day 1: Review of current research status
 - What do we know now; when will we know more?
 - What are the key research questions not being addressed currently?
 - What are the choke points that keep us from moving forward more rapidly?
 - Feasibility & realism
- Day 2: Priorities for research
 - Prevention trial sites
 - ARV issues
 - Research priorities vs. constraints
 - How do we move forward?





Biomedical Prevention Players




**Forum for Collaborative
HIV Research**

**School of Public Health &
Health Services**
**The George Washington
University**




Priorities to Advance the Field




- Support prevention trial sites
 - Long term commitment: donors & researcher plans
 - Understanding the local epidemic
 - Knowledge of host community
- Fill gaps in scientific knowledge
 - Combination vs. single ARV
 - Regulatory requirements
 - Cost-effectiveness
- Promote coordination while driving innovation
 - Organize, coordinate funding as resources expand
 - Maintain innovation and diversity in pre-clinical research
 - More fully engage industry
- Build ownership in host communities
- Prepare for global delivery

Choices Ahead: Donors, researchers, communities




- Prevention research “forum”?
 - Facilitate design and testing of combination products, share information, connect donors and stakeholders, reduce duplication in research agenda
- Measures to promote sustainable trial site capacity?
- Priorities for Phase III clinical sites?
- Addressing priority scientific and research challenges?
- New approaches for investigating combination and multicomponent interventions?
- Enhance local ownership?
- Ensure delivery and widespread use of new HIV prevention interventions?

Next Steps



- Ongoing dialogue with working group members
- Initiate and continue conversation with additional players
- Keep network active
- Establish smaller, focused working groups on specific topics




Forum Biomedical Prevention Working
Group Report:
New Era for HIV Prevention?

+ all Working Group Meeting Materials

- Available on www.hivforum.org
- For a hard copy of the report, email Meagan Lyon
mlyon@gwu.edu

Acknowledgments



- GATES FOUNDATION (Nick Hellmann, Renee Ridzon)
- All participants, presenters, discussants, moderators
- WG Co-chairs Mike Cohen, Ward Cates
- Meagan Lyon, Forum for Collaborative HIV Research
- Chris Collins